KDKoen Cedric Demaegd

Koen Cedric Demaegd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koen Cedric Demaegd has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tofersen treatment in respiratory onset amyotrophic lateral sclerosis and a variant of uncertain significance in SOD1; a case report

    by Sean W. Willemse, Koen C. Demaegd, Wouter Koole, Ruben P. A. van Eijk, Wouter van Rheenen, Jan H. Veldink, Leonard H. van Den Berg, Michael A. van Es


  • Open Access

    Small RNA sequencing identifies serum tDR-1:34-Gly-GCC tiRNA levels as a biomarker for survival in amyotrophic lateral sclerosis

    by Koen C. Demaegd, Lindy Kool, Sharada Baindoor, Paul D. Donovan, Junyi Su, Henk-Jan Westeneng, Ruben P.A. van Eijk, Grainne Geoghegan, Elena Perez Morrissey, Luise Halang, et al.

  • Open Access

    Bi-allelic intermediate ATXN2 repeat expansions are associated with slow progressing, leg-onset familial ALS

    by Koen Cedric Demaegd, Wouter Koole, Joke Jfa van Vugt, Jan Willem Dankbaar, Jeroen Hendrikse, A Nazlı Başak, Mamede de Carvalho, Philippe Corcia, Emilien Bernard, Claire Guissart, et al.

    Objectives: The identification of bi-allelic intermediate ATXN2 repeat expansions in a pedigree with amyotrophic lateral sclerosis (ALS) through clinical testing prompted us to investigate its relevance in the wider ALS population. Methods: ATXN2 repeat size was assessed in a large international cohort of ALS patients (n=6653 from Project MinE) and in neurologically intact control populations (n=13 515 controls from Project MinE and gnomad). For bi-allelic cases, we retrieved medical records, family history and MRI imaging. For familial cases, we obtained DNA samples from relatives for segregation analyses. Results: In total, we identified bi-allelic intermediate ATXN2 repeat expansions in five familial cases from three different pedigrees and five apparently sporadic cases. There is a relatively homogeneous phenotype characterised by lower limb onset and long survival (median 6 years) without significant cerebellar atrophy. Bi-allelic expansions were absent in controls (0 out of 13 515). Discussion: Here we report an apparently novel autosomal recessive form of familial ALS caused by bi-allelic intermediate ATXN2 repeat expansions, which is characterised by high penetrance, lower limb onset and slow progression. Although rare, testing for ATXN2 expansions should be performed in the clinical setting given its relevance to prognosis and genetic counselling.


  • Open Access

    An observational study of pleiotropy and penetrance of amyotrophic lateral sclerosis associated with CAG-repeat expansion of ATXN2

    by Koen C. Demaegd, Aoife Kernan, Johnathan Cooper-Knock, Joke J. F. A. van Vugt, Calum Harvey, Tobias Moll, David O’bRien, Sarah Gornall, Luke Drury, Sali M. K. Farhan, et al.

    Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) are both associated with a CAG-repeat expansion in ATXN2 and with TDP-43-positive neuronal cytoplasmic inclusions. The two disorders have been viewed as distinct entities, where an intermediate length expansion of 31-33 CAG-repeats is associated with sporadic ALS and a full length expansion of ≥34 CAG-repeats is associated with SCA2. We report the clinical phenotype of ATXN2-positive patients and their relatives, identified in three specialist ALS clinics, which force a reconsideration of this dichotomy. We also report the frequency of ATXN2 expansions in two large cohorts of ALS patients and in a population-matched cohort of controls. We report ten cases of familial ALS in which disease is associated with either an intermediate or a full-length ATXN2 CAG-repeat expansion. Pedigrees and patients feature additional phenotypes including parkinsonism, dementia and essential tremor (ET). We conclude that CAG-repeat expansions in ATXN2 exhibit pleiotropy and are associated with a disease spectrum that includes ALS, SCA2, and parkinsonism; to recognise this complexity we propose the new term ‘ATXN2-related neurodegeneration’. We also observed sporadic ALS associated with full-length expansions. We conclude that ATXN2 CAG-repeat expansions, irrespective of length, should be considered a risk factor for ALS. Interrupted CAG-repeats were associated with an ALS phenotype in our data but we also identified ALS cases with uninterrupted expansions. Our findings have relevance for researchers, patients and families linked to CAG-repeat expansions in ATXN2.


  • Open Access

    An observational study of pleiotropy and penetrance of amyotrophic lateral sclerosis associated with CAG-repeat expansion of ATXN2

    by Johnathan Cooper-Knock, Koen Demaegd, Aoife Kernan, Joke van Vugt, Calum Harvey, Tobias Moll, David O'BRien, Sarah Gornall, Luke Drury, Sali Farhan, et al.

    Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) are both associated with a CAG-repeat expansion in ATXN2 and with TDP-43-positive neuronal cytoplasmic inclusions. The two disorders have been viewed as distinct entities, where an intermediate length expansion of 31–33 CAG-repeats is associated with sporadic ALS and a full length expansion of ≧ 34 CAG-repeats is associated with SCA2. We report the clinical phenotype of ATXN2-positive patients and their relatives, identified in three specialist ALS clinics, which force a reconsideration of this dichotomy. We also report the frequency of ATXN2 expansions in two large cohorts of ALS patients and in a population-matched cohort of controls. We report ten cases of familial ALS in which disease is associated with either an intermediate or a full-length ATXN2 CAG-repeat expansion. Pedigrees and patients feature additional phenotypes including parkinsonism, dementia and essential tremor (ET). We conclude that CAG-repeat expansions in ATXN2 exhibit pleiotropy and are associated with a disease spectrum that includes ALS, SCA2, and parkinsonism; to recognise this complexity we propose the new term ‘ATXN2 spectrum disorder’. We also observed sporadic ALS associated with full-length expansions. We conclude that ATXN2 CAG-repeat expansions, irrespective of length, should be considered a risk factor for both familial and sporadic ALS. Interrupted CAG-repeats were not perfectly aligned with an ALS phenotype in our data. Our findings have relevance for researchers, patients and families linked to CAG-repeat expansions in ATXN2.

  • Familial motor neuron disease: co-occurrence of PLS and ALS (-FTD)

    by Eva M. J. de Boer, Koen C. Demaegd, Charlotte I. de Bie, Jan H. Veldink, Leonard H. van Den Berg, Michael A. van Es

    To report the frequency and characteristics of patients diagnosed with primary lateral sclerosis (PLS) with a positive family history for motor neuron diseases (MND) in the Netherlands and to compare our findings to the literature. Patients were identified through our ongoing, prospective population-based study on MND in The Netherlands, which also includes a standardized collection of patient characteristics, genetic testing, and family history. Only patients meeting the latest consensus criteria for definite PLS were included. The family history was considered positive for MND if any family members had been diagnosed with PLS, amyotrophic lateral sclerosis (ALS)(-FTD), or progressive muscular atrophy (PMA). Additionally, the literature was reviewed on PLS cases in which MND co-occurred within the same family. We identified 392 definite PLS cases, resulting in 9 families with a PLS patient and a positive family history for MND (2.3%). In only one of these pedigrees, a pathogenic variant (C9orf72 repeat expansion) was found. Our literature review revealed 23 families with a co-occurrence of PLS and MND, with 12 of them having a potentially pathogenic genetic variant. The consistent observation of PLS patients with a positive family history for MND, evident in both our study and the literature, implies the presence of shared underlying genetic factors between PLS and ALS. However, these factors are yet to be elucidated.


  • Open Access

    Transcellular Spreading of Tau in Tauopathies

    by Koen Demaegd, Joost Schymkowitz, Frederic Rousseau

    Tau, a microtubule‐associated protein playing a key role in a group of neurodegenerative diseases such as Alzheimer's disease, spreads throughout the brain, inducing pathology. A model akin to the spreading of prions has been raised owing to similar characteristics of inducing an abnormal protein conformation as a method of self‐amplification, spreading protein aggregates over anatomically linked pathways. The search to identify the “seeds” that induce conformational change has received much attention; however, less is known about the mechanisms by which tau is transmitted from cell to cell, so‐called “transcellular spreading”. In this review, we gather evidence regarding the spreading of tau throughout the brain and provide an overview of methods by which tau can be released from neurons as well as taken up. Furthermore, we bring together mechanisms of neurotoxicity behind tau spreading. Advancing our understanding about the spreading of tau can guide the search for therapeutic options for multiple neurodegenerative diseases aggregating tau.